NSE: APLLTD | BSE: 533573

Expensive Performer

Download real time

1018.05 11.50 (1.14%)

40.38% Gain from 52W Low

145.7K NSE+BSE Volume

NSE 30 May, 2025 3:31 PM (IST)

20,011.1

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

US FDA Approval

Alembic Pharma receives US FDA approval for Bosutinib Tablets, with a market size of $291 million See details

Alembic Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APLLTD, BSE:533573 Alembic Pharmaceuticals Ltd.

Search Inside the pdf :

Alembic Pharmaceuticals Ltd.

09 May 2025

1018.05

1.14%

Recovery underway, but cost discipline critical for margin expansion

Accumulate: Alembic Pharmaceuticals Ltd.

Target

KRChoksey

During Q4FY25, Alembic Pharma’s revenue stood at INR 17,696 Mn, up by 16.7% YoY (+4.5% QoQ), above our estimates by 11.6% driven by strong growth traction in the USA and Ex-USA segment. EBITDA stood at INR 2,719 Mn., up by 4.6% YoY (+4.5% QoQ), sharply above our estimates led by 34.7% led by higher-than-expected revenue and higher operating leverage.

Alembic Pharmaceuticals Ltd. has gained 31.18% in the last 3 Months

Alembic Pharmaceuticals Ltd.

07 May 2025

1018.05

1.14%

Alembic Pharma (BUY): FY26 to be better than FY25

Buy: Alembic Pharmaceuticals Ltd.

BOB Capital Markets Ltd.

Revenue/EBITDA/ PAT grew 6.7%/8% and 19% above our estimates. EBITDA margin reported 20bps above estimates of 15.4% in 4QFY25

Number of FII/FPI investors decreased from 213 to 198 in Mar 2025 qtr

Alembic Pharmaceuticals Ltd.

06 May 2025

1018.05

1.14%

Exports outshine; API witnesses gradual recovery

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered a better-than-expected performance in 4QFY25. A strong performance in export markets was offset partly by a muted show in domestic formulation (DF) segment.

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Alembic Pharmaceuticals Ltd.

12 Feb 2025

1018.05

1.14%

Alembic Pharma (BUY): Earnings recovery on normalised Azithromycin base

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

US and ROW sales grew above our estimates of 5% and 13% respectively, reporting growth of 10% each

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Alembic Pharmaceuticals Ltd.

06 Feb 2025

1018.05

1.14%

Challenges in API business weigh on the performance

Hold: Alembic Pharmaceuticals Ltd.

Target

KRChoksey

Alembic Pharma’s revenue missed our estimates (-2.2%) due to weak growth in domestic and API business. EBITDA fell short of our estimates due to a miss in revenue and higher operating expenses. Adj. PAT missed our estimates due to higher-than-expected tax expenses and lower-than-expected other income.

Alembic Pharmaceutic.. has an average target of 968.25 from 4 brokers.

Alembic Pharmaceuticals Ltd.

04 Feb 2025

1018.05

1.14%

In pursuit of a turnaround

Hold: Alembic Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q3FY25 result was dragged by tepid performance in India and API biz. India biz growth has been weaker (5.8% in 9MFY25) for the last couple of quarters due to pressure in acute segment even though animal health biz has been growing <20%.

Alembic Pharmaceuticals Ltd. has gained 15.71% in the last 1 Month

Alembic Pharmaceuticals Ltd.

03 Feb 2025

1018.05

1.14%

Muted India business and lower operating leverage drag earnings

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered operationally in-line 3QFY25 performance. Higher interest outgo and tax led to lower-than-expected earnings for the quarter.

Alembic Pharmaceuticals Ltd. has gained 15.71% in the last 1 Month

Alembic Pharmaceuticals Ltd.

08 Nov 2024

1018.05

1.14%

New launches in US and market share gains in Ex-USA will drive growth

Hold: Alembic Pharmaceuticals Ltd.

Target

KRChoksey

Alembic Pharma’s revenue missed our estimate (-4.8%) due to decline in API segment and moderate growth in India and US. However, EBITDA was in-line and Adj. PAT was largely in-line (+2.5%) with our estimate.